GlassScriptPhysician profile
Juan Escobar
NPI 1588661094
$2,521.27
in general payments reported to CMS, 2019-2025
15 companies · $92.11 in 2025
The $92.11 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $535 · 2021: $657 · 2022: $350 · 2023: $129 · 2024: $425 · 2025: $92.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $645.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $606.71 | 2019-2024 | |
| Abbott Laboratories | $464.75 | 2020-2025 | Diamondback Coronary |
| Allergan, INC. | $285.80 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $263.17 | 2021-2022 | |
| Heartflow, INC. | $248.07 | 2024 | |
| Amgen INC. | $125.00 | 2024 | Repatha |
| Boston Scientific Corporation | $113.00 | 2023 | Watchman Flx |
| Kerecis Limited | $111.32 | 2020 | |
| Organogenesis INC. | $108.25 | 2022 | |
| Penumbra, INC. | $101.16 | 2021 | |
| Abbvie INC. | $28.57 | 2021 | |
| Portola Pharmaceuticals, LLC | $21.41 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $16.28 | 2023 | Breztri |
| Exact Sciences Corporation | $15.33 | 2024 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Escobar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.